Rhythm Pharmaceuticals

Rhythm is developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.

 
 
  • ABOUT RHYTHM
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORY BOARD
  • PIPELINE
    • SETMELANOTIDE: A FIRST-IN-CLASS MC4 AGONIST
    • RARE GENETIC DISORDERS OF OBESITY
    • PUBLISHED RESEARCH
  • INVESTORS & MEDIA
    • INVESTOR OVERVIEW
    • STOCK INFORMATION
    • SEC FILINGS
    • NEWS & RESOURCES
    • EVENT CALENDAR
    • CORPORATE GOVERNANCE
    • SHAREHOLDER SERVICES
  • CAREERS
  • CONTACT
    • CONTACT RHYTHM
    • DIRECTIONS
INVESTORS & MEDIA > CORPORATE PROFILE

CORPORATE PROFILE

<< Back

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity.

Our lead product candidate, setmelanotide, is an investigational, first-in-class melanocortin-4 receptor (MC4R) agonist in development for the treatment of rare genetic disorders of obesity. We believe that setmelanotide, for which we have exclusive worldwide rights, has the potential to serve as replacement therapy that may restore lost activity in the MC4 pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. Variants in genes within the MC4 pathway result in the disruption of satiety signals and energy homeostasis in the body, which leads to unrelenting hunger, known as hyperphagia, and to severe, early-onset obesity.

We are initially focused on 6 rare genetic disorders of obesity for which there are currently no effective or approved treatments:

  • Pro-opiomelanocortin (POMC) deficiency obesity
  • Leptin receptor (LEPR) deficiency obesity
  • Bardet-Biedl syndrome
  • Alström syndrome
  • POMC heterozygous deficiency obesity
  • POMC epigenetic disorders

We have demonstrated proof of concept in Phase 2 clinical trials in POMC deficiency obesity, LEPR deficiency obesity, and Bardet-Biedl syndrome in which setmelanotide demonstrated reductions in both weight and hunger. Setmelanotide has been granted Breakthrough Therapy Designation for these indications by the US Food and Drug Administration.

Setmelanotide is currently in Phase 3 clinical trials for POMC deficiency obesity and LEPR deficiency obesity. We have also initiated a Phase 2 proof of concept basket study in Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. Additionally, we are evaluating another study for Prader-Willi syndrome.

  • INVESTORS & MEDIA
    • INVESTOR OVERVIEW
    • STOCK INFORMATION
    • SEC FILINGS
    • NEWS & RESOURCES
    • EVENTS & PRESENTATIONS
    • CORPORATE GOVERNANCE
    • ANNUAL REPORT AND PROXY
    • SHAREHOLDER SERVICES
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contact
Financial Tear Sheet

SITEMAP  /  TERMS OF USE  /  © 2018 RHYTHM PHARMACEUTICALS, INC. All Rights Reserved.